In this study we tested whether FMD in combination with anti-OX40/anti-PD-L1 or anti-PD-1/antiCTLA-4 improves the antitumor immune response against B16-F10 melanoma and LLC1 lung tumor and investigated its effect on cardiac adverse events. The gene discussed is TNFRSF4; the disease is melanoma.